Brokerages predict that Sarepta Therapeutics Inc (NASDAQ:SRPT) will post earnings of ($1.91) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Sarepta Therapeutics’ earnings, with the lowest EPS estimate coming in at ($2.18) and the highest estimate coming in at ($1.77). Sarepta Therapeutics posted earnings of ($0.85) per share during the same quarter last year, which suggests a negative year over year growth rate of 124.7%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, February 26th.
According to Zacks, analysts expect that Sarepta Therapeutics will report full-year earnings of ($8.41) per share for the current financial year, with EPS estimates ranging from ($8.53) to ($8.29). For the next fiscal year, analysts anticipate that the business will report earnings of ($5.54) per share, with EPS estimates ranging from ($7.75) to ($2.32). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Sarepta Therapeutics.
A number of analysts have recently weighed in on SRPT shares. Cantor Fitzgerald upped their price target on shares of Sarepta Therapeutics from $175.00 to $211.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. HC Wainwright upped their price target on shares of Sarepta Therapeutics from $160.00 to $260.00 in a research note on Friday, December 13th. Royal Bank of Canada reduced their price target on shares of Sarepta Therapeutics from $215.00 to $200.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Goldman Sachs Group reaffirmed a “buy” rating and issued a $180.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, December 24th. Finally, Bank of America reaffirmed a “buy” rating and issued a $187.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $197.81.
Hedge funds have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. lifted its stake in Sarepta Therapeutics by 34.6% during the third quarter. Envestnet Asset Management Inc. now owns 4,024 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 1,034 shares during the last quarter. Appleton Partners Inc. MA acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $268,000. Voya Investment Management LLC raised its holdings in shares of Sarepta Therapeutics by 10.3% during the third quarter. Voya Investment Management LLC now owns 38,062 shares of the biotechnology company’s stock valued at $2,867,000 after acquiring an additional 3,553 shares during the period. Atlantic Union Bankshares Corp acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $258,000. Finally, DNB Asset Management AS acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $1,386,000. 97.73% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:SRPT traded up $0.39 during trading on Tuesday, reaching $125.42. The company had a trading volume of 405,508 shares. The firm’s fifty day moving average is $123.92 and its 200 day moving average is $107.48. Sarepta Therapeutics has a twelve month low of $72.05 and a twelve month high of $158.80.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Further Reading: What are economic reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.